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ABSTRACT

SUB-EPIDEMIC GENERALIZED LOGISTIC-GROWTH MODEL PERFORMANCE FOR
INFLUENZA SEASON IN THE UNITED STATES, OCTOBER 2015–APRIL 2019
by
Hannah E. Fast
15 December 2020
INTRODUCTION: The public health response to an emerging infectious disease epidemic is
based on risk assessments that predict the severity of the health threat. Although infectious
disease surveillance data is often limited in scope, mathematical models can provide meaningful
information about epidemic growth dynamics to inform development of public health
interventions.
AIM: This investigation aims to validate application of a sub-epidemic version of the generalized
logistic-growth model (GLM) to a delineated period of epidemic growth representing the
influenza season, using national surveillance data for incidence of influenza-like illness (ILI) in
the United States.
METHODS: Surveillance data for ILI case counts were obtained from the Centers for Disease
Control and Prevention (CDC) website, FluView. GLM models with one, two, and three subepidemics were fit to four epidemic growth periods across four years, each containing 30 weekly
ILI incidence counts. Parameter estimates were obtained through nonlinear least squares curvefitting and sub-epidemic curves were aggregated into the best fit model. Model performance was
evaluated using calculation of performance metrics, bootstrapping, and visual analysis.
RESULTS: Model performance consistently improved across all four seasons as the number of
sub-epidemics incorporated into the GLM increased (n=1 to n=3). The parameter and subepidemic estimates provided information about the growth dynamics of the epidemic period,
identifying trends specific to each season.
DISCUSSION: The sub-epidemic GLM provides useful results about epidemic dynamics using
national case count data. In addition, while logistic growth models are often applied to discrete
outbreaks, the results of this investigation support application of the model to periods of
epidemic growth within seasonal trends as well. The findings support the continued use of this
model for academic and other public health application.
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CHAPTER I – INTRODUCTION
1.1 Description of the Public Health Problem
The emergence of an infectious disease outbreak poses serious risks for the health and
well-being of susceptible populations. An outbreak begins as a cluster of cases,
epidemiologically linked by time and place, that exceeds the endemic prevalence for the area
(CDC, 2011). Without public health intervention, an outbreak often shows exponential growth
and can quickly become an epidemic, a term indicating wider geographic spread, and eventually
evolve into a pandemic after achieving infections across multiple countries. Extensive, epidemic
spread is likely to have severe health, economic, and social consequences if transmission cannot
be brought under control. For this reason, epidemics are best dealt with preemptively and the
strength of the response benefits from early identification and institution of swift public health
interventions. Interventions encompass a wide range of policies and recommendations, such as
mandatory quarantines, school closures, outbreak vaccination clinics, travel restrictions, product
recalls, and limitations on the movement and sale of livestock.
To design effective interventions, public health researchers and authorities must
recognize that the response to an infectious disease does not occur in a vacuum; it occurs in a
highly complex social, political, and economic environment. Thus, designing an intervention in
theory can be much different than in practice, as each occurrence of an outbreak brings its own
idiosyncratic set of challenges. In 1990, sociologist Philip Strong observed the extraordinary
ways in which epidemics, referring to both the spread of disease and the strategies put in place to
control spread, disrupt public order and create the “medical version of a Hobbesian nightmare –
the war of all against all.” With such serious consequences, it is essential that all public health
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recommendations are grounded in scientific knowledge and that the processes for developing
that knowledge are widely validated and understood.
Amidst the challenges posed by an epidemic, the public health goal remains to derive
accurate, meaningful, and expert information from the constantly evolving stream of
epidemiologic data that is generated. The ability to rapidly disseminate accurate epidemiologic
research and analysis in a quickly evolving infectious disease outbreak or epidemic situation is
crucial to intervention development. This information will be used to make difficult decisions
regarding how to balance the costs and benefits of preventative measures, how to gain funding
and access to resources, and how to communicate to the public.
There have been extensive efforts in the field of epidemiology over the past few centuries
to specifically define what epidemiologic information is needed during an epidemic response.
Public health professionals are trained to use descriptive epidemiology to identify details
regarding the elements of person, place, and time (CDC, 2011). Brockmann and Helbing in 2013
developed these concepts further and described four key questions public health authorities must
ask in the event of an epidemic with potential for global spread:
“1) Where did the [novel] pathogen emerge?
2) Where are new cases to be expected?
3) When is an epidemic going to arrive at distant locations?
4) How many cases are to be expected?”
Three of the four questions involve some degree of prediction to determine where, when,
and to what extent the epidemic will spread. These predictions are likely to be informed by
statistical models, which are used to explore the relationship between an independent and a
dependent variable, predict outcomes, and determine the likelihood and error around that

2

outcome (Casals, Giraben-Farrés & Carrasco, 2014). Models are useful tools because they
simplify the complexity of transmission dynamics, allowing application to disparate geographic
regions, populations, and circumstances (Vynnycky & White, 2010).
In addition to defining relevant research questions, public health authorities also need to
be familiar with what data sources are available, as well as the time and resources required to
analyze the data to create meaningful, accurate findings. Questions to ask include: are existing
data sources sufficient or is the development of new data collection methods required? How
reliable are existing data sources? How much time would it take to develop new methods of data
collection, such as a survey or case report form? Useful epidemiologic analysis depends on the
identification of accurate data sources, as well as existing capacity for data access and
transmission among public health and healthcare partners. It also depends on a skilled workforce
for appropriate scientific analysis and the ability to successfully translate scientific findings into
information that can be consumed by a variety of audiences.
In recent years, public health has increasingly sought to develop advanced technological
methods and utilize big data for epidemiologic purposes. Vast technological advances in other
sectors of society have allowed for increased collection of health, demographic, and social
networking information, resulting in a proliferation of novel data sources for incorporation into
epidemiologic investigation and research. Forays into the use of big data to answer these key
questions in the event of an outbreak offer exciting and promising results. Some of the
developments in this field include researchers looking to implement complex and unsupervised
machine learning processes (Waldner, Osgood & Seitzinger, 2017). However, increased access
to data comes with the important caveat that more data does not always correlate to better results.
There are several important limitations that may not make these advanced methods suitable for
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all agencies and all public health responses. Novel data sources might not be able to be
reconciled with official or validated sources. National infectious disease surveillance systems
and infrastructure, such as the National Notifiable Diseases Surveillance System, are limited in
scope by interoperability challenges and the cost of updating data standards and collection
(Garcia et al., 2018). Furthermore, analysis of big data requires expert data management skills
and the ability to translate existing data fields into the form that is needed to answer scientific
questions. Appropriate use of big data can be severely limited by a shortage of computational
resources, lack of skilled staff, and challenges in validating and communicating the results.
While fully acknowledging the value of these technological advances, there is still a justified
need to examine how to efficiently and accurately obtain epidemiologic information from
relatively simple, validated, and consistent data sources.
The United States recently saw the importance of early-time infectious disease models
during the development of the novel COVID-19 pandemic in February and March 2020. In
March, U.S. governors, including Jay Inslee of Washington1, Gavin Newsom of California2, and
Andrew Cuomo of New York3, chose to make the difficult decision to implement mandatory
school and business closures and stay-at-home orders, with much of the U.S. following in their
footsteps shortly after. These high-risk decisions, for which the extent of the impact has yet to be
determined, were justified by caseload predictions informed by models. The global development
of COVID-19 reaffirms the importance of developing and validating infectious disease models

1

Example of March 2020 media coverage of Washington COVID-19 models: https://www.seattletimes.com/seattlenews/how-about-without-intervention-400-could-die-from-coronavirus-in-western-washington-by-april-7-studysuggests/
2
California example: https://www.nytimes.com/2020/03/19/us/California-stay-at-home-order-virus.html
3
New York example: https://www.nytimes.com/2020/03/31/world/coronavirus-live-news-updates.html
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prior to the emergence of major public health emergencies. This ensures officials will have the
information necessary to prevent morbidity, mortality, and other harms related to well-being.

1.2 Research Aim
This study aims to evaluate a sub-epidemic version of the generalized logistic-growth
model (GLM) developed by Chowell and Tariq (2019). The model will be fit to a delineated
period of epidemic growth within four influenza seasons, using U.S. influenza-like illness (ILI)
weekly incidence as a proxy. The study will compare the model performance results between the
GLM with 1 sub-epidemic curve to the modified GLM with 2 and 3 sub-epidemic curves. The
intent is to validate how incorporation of sub-epidemics into the model affects the utility of the
GLM for use on government case reporting data. The hypothesis is that the sub-epidemic model
will perform better than the single curve GLM. Gathering support for this model will help
strengthen the use of sub-epidemic methodology as a relatively quick and scalable approach to
improve understanding of epidemic growth dynamics and inform public health response efforts.
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CHAPTER II – LITERATURE REVIEW
2.1 Risk Assessment in an Epidemic
A sudden, unexpected rise in cases of an infectious disease is a cause for concern due to
the uncertainty of risk involved and the potential for harmful outcomes. The World Health
Organization (WHO) and other prominent scientific institutions have used the precautionary
principle framework to establish the necessity of public health action in an emergency despite the
presence of scientific uncertainty (Martuzzi and Tickner, 2004). In summary, the principle posits,
“in cases of serious or irreversible threats to the health of humans or ecosystems, acknowledged
scientific uncertainty should not be used as a reason to postpone preventative measures”
(Martuzzi and Tickner, 2004). The uncertain circumstances that surround the rapid development
of an infectious disease outbreak make the precautionary principle applicable. For example,
when the 2003 SARS epidemic began, little was known about the disease (Bensimon & Upshar,
2007). In Singapore, introduction of 1 index case into a hospital rapidly evolved into a healthcare
outbreak of 109 cases, despite infection control measures, and then spread into the community
(Goh, Cutter, & Heng et al., 2006). The demonstrated risk, despite scientific uncertainty, justified
implementation of strict control measures such as the closure of a 24-hour market and mandatory
quarantine of thousands who may have been exposed (Goh, Cutter, & Heng et al., 2006).
Subsequent analysis of the SARS outbreak in Singapore shows that the rapid control measures
were effective in slowing the spread. Lipsitch et al. (2003) found an initial effective reproductive
number of R=7 in the first week of the Singapore outbreak, later declining to R=1.6 in the second
week and R <1 in following weeks. Precautionary action to introduce control measures in a highrisk situation ultimately reduced harm to the community and was able to control and stop spread
of the disease.
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As the precautionary principle is defined broadly and theoretically, there is much
discussion within the scientific and legal community about how to apply the principle
objectively. Critics of the principle argue that aggressive use of precaution can be harmful,
(Wilson et al., 2019) while others have made the case that historically, existing assumptions
about causality, which precautionary action might draw upon, have had to be overturned in order
to stop disease transmission and advance scientific understanding (Goldstein, 2012). From a
legal perspective, Kegge (2020) argues a standard of proof must be met to use the precautionary
principle as justification. That standard is based on a risk assessment that shows a significant
level of risk. In other words, evoking the precautionary principle requires a threshold of severity.
In an outbreak, this implies that the consequences of uncontrolled disease spread to the public’s
health must outweigh any potential costs or damage caused by control measures (Fischer &
Ghelardi, 2016). Overall, outbreak response is highly dependent on accurate and validated
methods of estimating risk.
Risk assessments during the early growth period of an epidemic are often informed by
mathematical models (Chowell et al., 2016b). Statistical models that use principles of
exponential growth are able to define the relationship between cases of disease and time,
providing insight into transmission dynamics. This information makes it possible to gauge the
severity of the health threat by estimating epidemic size, anticipated growth rate, and the
likelihood of clinical outcomes such as hospitalization, disability, and death. During the early
stage of an epidemic, when data on case-patient outcome is likely to be incomplete, models may
be able to provide more accurate information than crude calculations. For example, during onset
of COVID-19, Verity et al. (2020) estimated case fatality rates using a parametric model because
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the crude case fatality rates calculated during past respiratory disease epidemics (e.g., SARS and
H1N1 influenza) were later found to be underestimated.
A wide range of different model structures are used within the field of infectious disease
modeling. Thus, after defining the research question and appropriate data sources, analysis
design must take into account how to select an appropriate model structure for the investigation.
Vynnycky & White (2010) describe the process of choosing a model structure as dependent on
the natural course of the infection and the time period being investigated. For example, a model
structure will need to take into consideration the length of the incubation period and whether
infected individuals will return to the susceptible population. If this information is not available,
as is the case with a novel pathogen, or data is incomplete, parsimonious models are able to
account for these limitations by incorporating built-in assumptions into the model.
The exponential growth model is a phenomenological model, which means it is a
mathematical model that can describe the relationship between an independent and dependent
variable (Chowell et al., 2016a). A phenomenological model is able to derive all of the necessary
information from case count data because it makes assumptions about the transmission based on
mathematical principles of exponential growth, rather than parameters that need to be defined
based on an understanding of the natural history of the infection. This makes the model a
promising candidate for use in situations where data is limited, such as the case of a novel
epidemic where existing knowledge on the disease is limited. The exponential growth model is
able to provide meaningful information during the initial phase of outbreak when case counts
grow exponentially within the population and outcomes such as recovery and death are still
limited (Bertozzi et al., 2020). Bertozzi et al. (2020) identified exponential growth as a one of
three parsimonious models that was effective to use with COVID-19 early-time local and
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national government case data. Their selection of the model was based on the criteria that the
model be relatively simple, require few parameters, and have the ability to be scaled to
accommodate varying region sizes.
Epidemics often show exponential behavior during the growth period, such as the 2014
Ebola epidemic (Hunt, 2014) and the 2009 H1N1 pandemic (de Picoli Junior et al., 2011). It is
also common to see sub-exponential behavior, depending on the circumstances in which the
epidemic is occurring. For example, sub-exponential behavior was observed during the
emergence of COVID-19 in mainland China (Maier & Brockmann, 2020) and Ebola in Uganda
(Viboud, Simonsen & Chowell, 2016). The generalized logistic-growth model distinguishes
between exponential and sub-exponential growth by the inclusion of a growth scaling factor into
the model (Viboud, Simonsen & Chowell, 2016). This allows the model to be scaled to a many
different diseases and situations.

2.2 Sub-epidemic Model Development
Chowell and Tariq (2019) introduced a novel sub-epidemic modeling framework that
aggregates multiple sub-epidemic curves to better fit overall incidence data. In the initial
investigation, the sub-epidemic model was found to perform better than simple logistic-growth
models when applied to historical outbreaks of SARS, Ebola, and Plague. The sub-epidemic
model is fit to epidemic curve data. The epidemic curve, a histogram which shows incidence of
cases over time, is one of the simplest tools used frequently by epidemiologists (CDC, 2011).
The epidemic curve has remained a foundational tool for summarizing the distribution of cases
because it is multi-functional and mathematical analysis of the epidemic curve is able to provide
information about modality, generation time, and growth rate. In reality, the growth of an
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epidemic is complex, with transmission occurring in various settings and among different
populations with different beliefs and types of social interactions. The sub-epidemic model
identifies mathematical variation within an aggregate epidemic curve and highlights ways the
distribution might be broken down to show differences in transmission dynamics between subpopulations. This information could be used to identify different transmission settings, target
interventions, and generate hypotheses. While visual analysis of the epidemic curve is able to
provide some answers to the key questions during an epidemic, mathematical analysis informed
by a model will be able to provide more comprehensive epidemiologic information.
The sub-epidemic model is a modified version of the generalized logistic-growth model
(GLM) that creates estimates for a specified number (n) of sub-epidemics within one overall
epidemic curve (Chowell & Tariq, 2019). Model fit is determined by aggregating the subepidemics and comparing the fit of the aggregate curve to the actual data. Figure 1 contains an
example of the differences between these two approaches, with 1 GLM curve on the left
compared to an aggregated curve from 2 sub-epidemics on the right. It is important to note in
Figure 1 that both models were generated using the same source data. The model estimates three
parameters for each sub-epidemic: r, the growth rate, p, a growth scaling factor, and K, the total
epidemic size. Thus, the total number of parameters estimated for the model will be 3n, or 3
times the number of sub-epidemics. Increased parameters come at a cost to the model’s utility.
As the model derives all of its information from the available data, parameter estimation
becomes less reliable as more parameters are required to be estimated. The multiplication of
parameters as the number of sub-epidemics increases can lead to parameter identifiability
challenges and increase model uncertainty (Roosa & Chowell, 2019).
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When the number of sub-epidemics is 1 (n=1), the model represents the GLM, with
equation

𝑑𝐶(𝑡)
𝑑𝑡

= 𝑟 × 𝐶(𝑡)𝑝 × (1 −

𝐶(𝑡)
𝐾

) and C(t) representing the incidence over time. As shown

on the right in Figure 1, only one curve is generated to fit the data. As the number of subepidemics increases, the equation incorporates an index, i:

𝑑𝐶𝑖 (𝑡)
𝑑𝑡

= 𝑟𝑖−1 × 𝐶𝑖 (𝑡)𝑝 × (1 −

𝐶𝑖 (𝑡)
𝐾𝑖

). In

the sub-epidemic version, multiple curves using the GLM equation are used to fit the data.

Figure 1 Example of sub-epidemic curve aggregation using SARS outbreak data, for n=1 and n=2.

2.3 Application to Seasonal Influenza
Influenza is a viral respiratory disease caused by the family of influenza viruses,
including influenza A and influenza B viruses. Transmission dynamics for influenza are
complex, partially due to frequent mutations and circulation of multiple strains, and partially due
to the effect of environmental and behavioral changes on influenza transmission (Lofgren et al.,
2007). There is an observed seasonality to influenza spread in the United States, with increased
transmission beginning in the fall and winter months of each year. The seasonality occurs for
several reasons, including the effect of humidity and temperature on spread (Lowen et al., 2007)
and increased human susceptibility and the increase in behavior (e.g., crowding) that is
conductive to spread (Lofgren et al., 2007). Thus, although influenza is being transmitted year-
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round, periods of epidemic growth occur due to both the effect of seasonality and potential
introduction of new strains into susceptible populations.
For influenza, the average generation time is 3 days (Nasserie et al., 2017). This means
that fluctuations in growth rate can cause epidemics of high magnitude quickly. It is often
identified as the pathogen of interest in planning for novel pandemics because the disease
is “more likely to occur than other pathogen types and which is also relatively likely to result in a
large epidemic” (Biggerstaff et al., 2019). With national surveillance data delayed by 1 to 2
weeks, staying aware of influenza transmission dynamics to provide nowcasts and forecasts is
important for situational awareness (Leuba et al., 2020). Severity assessments of influenza
inform resource distributions of vaccination, hospitalization bed availability, antivirals, and assist
with communication to the public (Barr & Cheng, 2018). The sub-epidemic GLM is one
approach to assess influenza dynamics in real time and inform public health response.
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CHAPTER III – METHODS AND PROCEDURES
3.1 Influenza-like Illness (ILI) Surveillance Data
The national surveillance system for influenza activity in the U.S. includes eight
components and monitors five types of data sources: virologic testing, outpatient visits,
geographic spread of disease, hospitalizations, and mortality reporting (National Center for
Immunization and Respiratory Diseases [NCIRD], 2020a). One of these components is the U.S.
Outpatient Influenza-like Illness Surveillance Network (ILINet), which is comprised of nearly
3,000 outpatient healthcare providers that voluntarily report to CDC weekly. ILINet surveillance
data includes the total number of outpatient visits to the provider per week and of these, the
number of patients with ILI. ILI is defined as a fever greater than 100º F and cough and/or sore
throat, without another known cause (NCIRD, 2020a). It is important to note that ILINet counts
are not laboratory-confirmed and should not be interpreted as influenza incidence, as ILI is nonspecific and could potentially have another cause. In addition, only a subset of healthcare
providers participates in the surveillance system and many individuals do not seek out healthcare
or receive laboratory testing for influenza when ill. While measures of ILI do not capture the
magnitude of influenza transmission, fluctuations in ILI activity over time can be used as a proxy
to study overall patterns and trends in the influenza season (World Health Organization [WHO],
2015). Thus, because the logistic-growth model captures growth dynamics over time, the change
in ILI counts from week to week can offer insight into seasonal dynamics for influenza.
ILINet summary-level data are published on two FluView Interactive dashboards4,5 and
made available for public use. For this investigation, national ILI counts by week were obtained

4

National, Regional, and State Level Outpatient Illness and Viral Surveillance: https://gis.cdc.gov/grasp/fluview/
fluportaldashboard.html
5
Age Group Distribution of Influenza Positive Tests Reported by Public Health Laboratories:
https://gis.cdc.gov/grasp/fluview/flu_by_age_virus.html
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from FluView Interactive for four influenza seasons: 2015–2016, 2016–2017, 2017–2018, and
2018–2019. Data on virus characterization, age group, and geographic region were also obtained
for supplemental analysis.
Since ILI activity occurs year-round, the fall and winter influenza season for each year
was delineated and analyzed as an epidemic period. The epidemic period was defined beginning
in early October at Morbidity and Mortality Weekly Report (MMWR) Week 40, which is the
start of the influenza reporting period for each season, through late April, MMWR Week 17, of
the next year (NCIRD, 2020a). Each season contained a total of 30 data points. The specific start
and end dates for each season are listed in Table 1. A baseline adjustment was made so that the
ILI incidence for all 30 weeks within the season was decreased by 1 less than the epidemic week
0 incidence. After the adjustment, each epidemic period started at a count of 1 (Figure 3). This
was done to counter the inflation of growth dynamics for the first data point, which occurred
when the epidemic period was removed from seasonal context and no longer able to be analyzed
in relation to the preceding week.
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Reported ILI Incidence

90000
80000
70000
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Jul-19
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Jan-18

Oct-17

Jul-17

Apr-17

Jan-17

Oct-16

Jul-16

Apr-16

Jan-16

Oct-15

0

Analyzed as Epidemic Period

Figure 2 Influenza seasons were delineated by week of report and analyzed as an epidemic period. Each
season started in early October (MMWR Week 40) and ended in late April (MMWR Week 17) of the next
year.
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Table 1 Date of start, peak, and end of the delineated seasons. The date corresponds to the Saturday at the end
of the week of report (MMWR Week).
Season
2015–2016
2016–2017
2017–2018
2018–2019

Week of Season Start /
MMWR Week (Date)
0 / 40 (10-10-15)
0 / 40 (10-8-16)
0 / 40 (10-7-17)
0 / 40 (10-6-18)

Week of Season Peak /
MMWR Week (Date)
22 / 10 (3-12-16)
18 / 6 (2-11-17)
18 / 6 (2-10-18)
19 / 7 (2-16-19)

Week of Season End /
MMWR Week (Date)
29 / 17 (4-30-16)
29 / 17 (4-29-17)
29 / 17 (4-28-18)
29 / 17 (4-27-19)

# Data Points
30
30
30
30

50000
45000

Reported ILI Incidence

40000
35000
30000
25000
20000
15000
10000
5000

Incidence
Adjustment

Aug-16
Sep-16
Oct-16
Nov-16
Dec-16
Jan-17
Mar-17
Apr-17
May-17
Jun-17

0

Figure 3 The reported ILI incidence was adjusted so that each season started at a value of 1.

3.2 Fitting the Model
Analysis was conducted using MATLAB, with code development supported by Dr.
Gerardo Chowell and Kimberlyn Roosa at Georgia State University School of Public Health. The
sub-epidemic generalized-logistic growth equation,

𝑑𝐶𝑖 (𝑡)
𝑑𝑡

= 𝑟𝑖−1 × 𝐶𝑖 (𝑡)𝑝 × (1 −

𝐶𝑖 (𝑡)
𝐾𝑖

), was

created into a function. A simple two column matrix with time in one column and case counts in
another was created for each epidemic period, and prior to analysis, the measure of time was
converted from weeks to days. Parameter values were estimated for r, the growth rate, p, the
growth scaling factor, and K, the total epidemic size, for n sub-epidemics. The number of subepidemics was specified as 1, 2, and 3 sequentially for each dataset, which resulted in estimation
of 3, 6, and 9 parameters, respectively. Parameter estimates were obtained through nonlinear
least squares curve-fitting of the epidemic period using the MATLAB lsqcurvefit function. This
function identifies the set of parameters that produce a model with the least summed differences
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between the estimated data point and the actual source data at each point in time (Roosa &
Chowell, 2019). Starting parameter estimates for the least squares curve-fitting process were
randomly generated from a continuous uniform distribution using the unifrnd function in
MATLAB. Since the solver is sensitive to the starting values, the random generation of these
values meant model outcomes often differed across runs. To account for this, each model
scenario was generated a minimum of 10 times and the best fit for that scenario was chosen
using a comparison of residuals, performance metrics, and parameter identifiability metrics, as
described in a following section. Upper and lower bounds for the parameters were defined as
follows: 0 < r < 10; 0 < p < 1; 1 < K < cumulative count for the epidemic period. C(t) was
defined as the starting incidence divided by the number of sub-epidemics (n).
After the best fit parameter estimates were identified, an ordinary differential equation
solver (ode45 function in MATLAB) used these estimates to calculate cumulative incidence
curves for each sub-epidemic. Cumulative incidence was transformed into weekly incidence and
plotted. Finally, weekly incidence for all sub-epidemics was summed to produce the aggregate
model.
Parametric bootstrapping was conducted to provide additional information on model fit
and parameter identifiability metrics. During the bootstrapping process, two hundred simulated
datasets were generated from the aggregate incidence curve using a Poisson error structure.
Then, the model fit process was repeated for each simulated dataset, which resulted in 200
estimates for each parameter value and 200 incidence curves. These curves were used to
calculate a 95% CI around the model and the best fit parameter value.
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3.3 Model Comparison and Performance Metrics
Four performance metrics were used to assess model fit: root-mean-square error (RMSE),
mean absolute error (MAE), mean interval score (MIS), and 95% confidence interval (CI)
percent coverage (Chowell & Tariq, 2019). All four metrics were used together to provide a
comprehensive assessment of model performance. In addition, qualitative and visual analysis of
fit, residual variance, and parameter confidence interval widths also informed model selection
and interpretation.
The RMSE and MAE are statistics that measure the average magnitude of distance
between the model and the underlying data point (Willmott & Matsuura, 2005). The RMSE
equation averages the squared residuals and then takes the square root. This is represented in the
2

following equation, 𝑅𝑀𝑆𝐸 = [∑𝑛𝑖=0 (𝑧𝑓𝑖 − 𝑧𝑜𝑖 ) /𝑛]1/2] (Barnston, 1992). The MAE takes the
absolute value of the residuals, 𝑀𝐴𝐸 = [∑𝑛𝑖=0|𝑧𝑓𝑖 − 𝑧𝑜𝑖 |] (Willmott & Matsuura, 2005). Since
both the RMSE and MAE represent the magnitude of the residuals, lower values for these
metrics indicate better model performance because a better fit to the data will minimize the
distance between the model and data points. Qualitative analysis of the distribution of residuals
also informed model selection. Model fits with residuals showing constant variance and random
distribution were preferred over model fits showing residuals with nonconstant variance, even if
RMSE and MAE were similar in magnitude. These three methods of evaluation were applied to
the best fit models.
The remaining two metrics, MIS and 95% CI percent coverage, were obtained after the
bootstrapping process. The MIS calculates the width of the 95% confidence interval generated
from the 200 model curves that were fit to the simulated datasets. The metric scores whether or
not data points fall into that interval and how close they fall to the bounds. The MIS follows the
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1

2

2

equation, 𝑀𝐼𝑆 = ℎ ∑ℎ𝑖=0(𝑈𝑡𝑖 − 𝐿𝑡𝑖 ) + 0.05 (𝐿𝑡𝑖 − 𝑦𝑡𝑖 )𝐼{𝑦𝑡𝑖 < 𝐿𝑡𝑖 } + 0.05 (𝑦𝑡𝑖 − 𝑈𝑡𝑖 )𝑈{ 𝑦𝑡𝑖 < 𝑈𝑡𝑖 }
(Chowell & Tariq, 2019). If the data point falls outside the lower or upper bounds of the interval,
it is assigned 1 point. In addition, the MIS incorporates a calculation of the difference between
the upper and lower bounds, meaning that narrow intervals will have a lower score while wider
intervals will have a higher score. Overall, a lower MIS indicates better performance. Lower
scores are obtained from a narrower 95% CI with less variation and may also be indicative of the
95% confidence interval’s ability to represent the underlying data points. Similarly, the 95% CI
percent coverage captures the percent of data that falls into the bounds of the 95% CI. A model
with high percent coverage indicates a good fit while decreasing percent coverage would be
interpreted as weaker model performance. Comparison of the width of the 95% CI around the
parameter estimates provided information about parameter identifiability, with a wider 95% CI
indicating increased uncertainty around the value of the estimate (Roosa & Chowell, 2019).
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CHAPTER IV – RESULTS
4.1 Description of Epidemic Curves
The growth curve of reported ILI incidence was skewed left for all four seasons, with
epidemic peak occurring after the midway point, at epidemic week 22, 18, 18, and 19 for the
2015 to 2018 seasons, respectively. The 2018–2019 season had the highest cumulative incidence
of ILI, closely followed by the 2017–2018 season, which also had the steepest curve and highest
peak. The 2015–2016 season had both the latest peak and the lowest peak.

Figure 4 Comparison of ILI trends across years. This figure represents reported incidence, not adjusted. A)
Weekly incidence on a linear scale. B) Cumulative incidence on a linear scale. C) Cumulative incidence on a
log-linear scale.
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4.2 Parameter Estimates
Across the four years that were analyzed, best fit estimates for r, the growth rate, ranged
from 0.0695 to 6.33, with a median of 0.2485. Best fit estimates for p, the growth scaling factor,
ranged from 0.466 to 1.00, with a median of 0.8845. Lastly, best fit estimates for K, total
epidemic size, ranged from 5,353 to 627,515, with a median of 166,167. Best fit estimates from
each model are shown in Figure 5 and Table 2.
With the sub-epidemic model, parameter estimates are expected to vary within one
season as sub-epidemics can take many different shapes within an aggregate curve. However,
there are observable patterns across parameter estimates related to the shape of the aggregate
curve. For example, the 2015–2016 season had both the highest estimates for r and the lowest
estimates for p of the four years. Although the overall shape of this curve is the most gradual of
all the seasons, it had the latest peak and therefore the longest left tail. The sub-epidemic curve
generated to fit this tail had a high r value (6.33 for 1 curve when n=2; 6.23 for 1 curve when
n=3) but when paired with a low p (0.473 for 1 curve when n=2; 0.466 for 1 curve when n=3),
this created a wide and gradual curve. This relationship between r and p was also seen in the 3
sub-epidemic model of the 2018–2019 season, where a relatively high r value (2.877 for 1 curve
when n=3) was paired with a relatively low p value (0.633 for 1 curve when n=3) to create a
small and gradual curve to fit the skewed left tail of that season.
The 2017–2018 season had the highest peak and the steepest incline. This resulted in the
largest estimate for K, total epidemic size, when n=1 because the one sub-epidemic curve
generated also had a high peak. Individual estimates for K typically decreased as the number of
sub-epidemics increased, as the aggregate incidence curve would then have multiple subepidemics contributing to its height and shape.
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Figure 5 Distribution of sub-epidemic parameter estimates obtained from the best fit model. A) Estimates for
r, the growth rate. B) Estimates for p, the growth scaling factor. C) Estimates for K, total epidemic size.
Table 2 Values for sub-epidemic parameter estimates obtained from the best fit model.
Growth Rate
Growth Scaling Factor
Season
Model Type
(r)
(p)
2015–2016 GLM 1 Sub-Epidemic
r: 0.180
p: 0.887
GLM 2 Sub-Epidemics
r1: 6.33
p1: 0.473
r2: 0.0839
p2: 1.00
GLM 3 Sub-Epidemics
r1: 6.23
p1: 0.466
r2: 0.218
p2: 0.894
r3: 0.0885
p3: 0.996
2016–2017 GLM 1 Sub-Epidemic
r: 0.330
p: 0.837
GLM 2 Sub-Epidemics
r1: 0.116
p1: 0.967
r2: 1.40
p2: 0.667
GLM 3 Sub-Epidemics
r1: 0.675
p1: 0.767
r2: 0.104
p2: 0.997
r3: 0.0775
p3: 0.998
2017–2018 GLM 1 Sub-Epidemic
r: 0.279
p: 0.882
GLM 2 Sub-Epidemics
r1: 0.881
p1: 0.755
r2: 0.111
p2: 1.00
GLM 3 Sub-Epidemics
r1: 0.113
p1: 1.00
r2: 0.676
p2: 0.788
r3: 0.0695
p3: 1.00
2018–2019 GLM 1 Sub-Epidemic
r: 0.331
p: 0.831
GLM 2 Sub-Epidemics
r1: 1.01
p1: 0.720
r2: 0.951
p2: 0.680
GLM 3 Sub-Epidemics
r1: 0.204
p1: 0.900
r2: 2.877
p2: 0.633
r3: 0.154
p3: 1.00
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Total Epidemic Size
(K)
K: 195,728
K1: 163,407
K2: 98,353
K1: 168,926
K2: 5,353
K3: 99,417
K: 336,989
K1: 133,615
K2: 232,218
K1: 120,095
K2: 137,775
K3: 84,230
K: 627,515
K1: 386,564
K2: 275,307
K1: 289,733
K2: 334,404
K3: 34,211
K: 223,450
K1: 449,210
K2: 108,699
K1: 478,771
K2: 61,192
K3: 63,499

4.3 Model Performance Metrics
The performance metric results represent model outcomes from both the least squares
curve-fitting process and the bootstrapping process. As the number of sub-epidemics
incorporated into the model increased, the magnitude of error as measured through RMSE and
MAE decreased. MIS also showed a consistent decrease, indicating that the 95% CI around the
best fit model became narrower as the number of sub-epidemics increased. Overall, the model
95% CI did not capture a high percentage of the underlying data, with a maximum of 17%. For
two seasons, 2015–2016 and 2016–2017, percent coverage slightly increased as number of subepidemics increased. For the other two seasons, 2017–2018 and 2018–2019, percent coverage
stayed consistent for all values of n. The results for fit, residual variance, and width of 95% CI
around parameter estimates are included in season-specific figures.
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Figure 6 Model performance metrics for four seasons with number of sub-epidemics increasing from n=1 to
n=3. A) RMSE results. B) MAE results. C) MIS results. D) 95% CI percent coverage results.
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Table 3 Model performance metrics for the four seasons.
Season

Model Type

RMSE

MAE

MIS

95% CI Coverage

2015–2016

GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

2246.8
667.9
654.1

1794.6
519.1
500.2

67416
15499
14782

13.3%
13.3%
16.7%

2016–2017

GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

2793.0
2005.4
1417.4

2516.3
1511.5
1194.6

94311
54052
41337

6.7%
13.3%
16.0%

2017–2018

GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

6043.4
2193.6
2052.3

4789.2
1841.6
1586.2

183221
65133
55241

6.7%
6.7%
6.7%

2018–2019

GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

5609.4
2974.4
2118.6

4838.5
2458.5
1569.9

185222
89619
53515

6.7%
6.7%
6.7%
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4.4 2015–2016 Season Results
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Figure 7 2015–2016 results. A) Sub-epidemic curves generated by fitting the model with 1, 2, and 3 subepidemics (L to R). The red line is the aggregate curve. B) Residuals from model fit to epidemic period data,
sub-epidemics 1, 2, and 3 (L to R). C) Parameter estimates (marked by x) and 95% confidence intervals
generated by bootstrap method using 200 simulated datasets. First chart shows r, sub-epidemics 1, 2, and 3,
followed by similar charts for p and K.
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4.5 2016–2017 Season Results
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Figure 8 2016–2017 results. A) Sub-epidemic curves generated by fitting the model with 1, 2, and 3 subepidemics (L to R). The red line is the aggregate curve. B) Residuals from model fit to epidemic period data,
sub-epidemics 1, 2, and 3 (L to R). C) Parameter estimates (marked by x) and 95% confidence intervals
generated by bootstrap method using 200 simulated datasets. First chart shows r, sub-epidemics 1, 2, and 3,
followed by similar charts for p and K.
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4.6 2017–2018 Season Results
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Figure 9 2017–2018 results. A) Sub-epidemic curves generated by fitting the model with 1, 2, and 3 subepidemics (L to R). The red line is the aggregate curve. B) Residuals from model fit to epidemic period data,
sub-epidemics 1, 2, and 3 (L to R). C) Parameter estimates (marked by x) and 95% confidence intervals
generated by bootstrap method using 200 simulated datasets. First chart shows r, sub-epidemics 1, 2, and 3,
followed by similar charts for p and K.
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4.7 2018–2019 Season Results
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Figure 10 2018–2019 results. A) Sub-epidemic curves generated by fitting the model with 1, 2, and 3 subepidemics (L to R). The red line is the aggregate curve. B) Residuals from model fit to epidemic period data,
sub-epidemics 1, 2, and 3 (L to R). C) Parameter estimates (marked by x) and 95% confidence intervals
generated by bootstrap method using 200 simulated datasets. First chart shows r, sub-epidemics 1, 2, and 3,
followed by similar charts for p and K.
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4.8 Comparison to Virologic Surveillance
Model results were generated by fitting to adjusted ILI incidence data. Because ILI is
nonspecific, a comparison was made to the virologic surveillance data reported by public health
laboratories during the same time period. Counts and type of influenza-positive viral specimens
was obtained from FluView and grouped as A (H3), A (H1N1), A (No Subtyping Done), and B
(All Types). Selected results are displayed in Figure 11 with additional results included in the
Appendix.
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Figure 11 Counts and types of viral specimens reported to CDC each week from public health laboratories.
The best fit sub-epidemic model results obtained from fitting to the adjusted ILI incidence data are shown in
grey. One model from each year was selected for the figure, depending on which was most aligned to the
virologic data. A) 2015–2016 season, 2 sub-epidemic model. B) 2016–2017 season, 3 sub-epidemic model. C)
2017–2018 season, 2 sub-epidemic model. D) 2018–2019 season, 3 sub-epidemic model.
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CHAPTER V – DISCUSSION AND CONCLUSIONS
5.1 Discussion of Key Findings
There was a demonstrated improvement in model performance when sub-epidemics were
incorporated into the GLM. As the number of sub-epidemics increased from 1 to 3, the distance
between the aggregate model curve and the underlying incidence data decreased. The observed
improvement in model fit is likely because the sub-epidemic model has more parameters than the
1 curve GLM and is therefore able to capture more variation in the data. This is one of the
benefits of using the sub-epidemic model for influenza, as factors such as different virus types,
seasonal effects, and changing vaccination coverage, can easily cause variation in the shape of
the incidence curve. While the improvement in model performance is notable, improved fit does
not necessarily indicate epidemiologic information has been gained. Thus, an additional benefit
of the sub-epidemic model is its ability to identify and visualize complex epidemic growth
dynamics from simple case count data. While the sub-epidemic curves were not always able to
be traced back to an underlying epidemiologic cause, several results from this investigation
support the conclusion that incorporation of 2 or 3 sub-epidemics into the model enhanced
identification of unique seasonal characteristics.
The 2015–2016 season peaked in mid-March, which happened only two other times in
the previous 18 influenza seasons (Davlin et al., 2016). While the GLM with n=1 was not able to
capture both the longer left tail and the peak of the season, the GLM with n=2 and n=3 fit subepidemic curves to both components. The comparison of the model to the virologic data
indicates that the left tail observed in the ILI data for this season may not have been caused by
influenza, due to the absence of reported viral specimens during that time (Figure 11A). Instead,
this feature was likely a result of using standard season start and end dates that were not specific

29

enough for each year. However, despite the inclusion of ILI noise at the start of this season, the
sub-epidemic model separated that component out into its own sub-epidemic. This is helpful
because it was able to fit the left tail and peak separately, which helps to limit the effects of ILI
noise on parameter estimation for peak growth dynamics.
Comparison of the virologic surveillance data to the 3 sub-epidemic model for the 2016–
2017 season showed that the model was able to successfully identify individual peaks for A (H3)
viruses and B viruses (Figure 11B). This season primarily consisted of influenza A (H3N2)
viruses, but a small wave of influenza B activity was seen late in the season, from the end of
March through May (Blanton et al., 2017). The model identified a small sub-epidemic curve later
in the season, which aligned with the timing of the emergence of the influenza B virus wave. In
addition, for this season, the narrow confidence interval around each parameter estimate supports
the identifiability of the results, even with 9 parameters being estimated from the data. Similar
results were seen for the 2017–2018 season, where both sub-epidemics from the 2 sub-epidemic
model aligned with peak timing for two waves seen in the viral results: an initial influenza A
(H3N2) virus wave followed by an influenza B wave (Figure 11C) (Garten et al., 2018).
The 2018–2019 influenza season was also characterized by two waves of activity,
however both due to influenza A viruses. During this season, there was an initial wave
of influenza A (H1N1), followed by a second wave of influenza A (H3N2) viruses (Xu et al.,
2019). The 2 and 3 sub-epidemic models did not distinguish the two waves, instead combining
both into one large sub-epidemic (Figure 11D). This is likely because the ILI incidence was not
able to capture the distinction between the two waves, since the peaks of both waves were
relatively close, separated by 7 weeks, and of similar magnitude. The similarities in growth
patterns between the two waves mean the curves would share transmission dynamics and similar
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parameter estimates. It is possible that the sub-epidemic curves indicate another component of
transmission, such as variation due to different spread among age groups or across different
regions. However, a brief analysis of the curve stratified by age group and HHS regions
components did not show any notable differences from the overall ILI incidence curve. Although
the model combined the two viral activity waves into one, Figure 10C shows wide 95% CIs
around the parameter estimates for r, p, and K, indicating uncertainty. The uncertainty around
estimates for this season is much higher than the uncertainty for the 3 sub-epidemic model for
the two previous seasons. Thus, this finding supports the continued use of parameter
identifiability metrics, as these metrics provided crucial information about the certainty of the
model results. For both seasons where the models did not align closely with virologic
surveillance, 2015–2016 and 2018–2019, uncertainty around the parameters was much higher
than for the other two seasons that were aligned with activity waves observed in the virologic
surveillance.
5.2 Strengths and Limitations
This investigation used national ILI surveillance data to validate the use of the subepidemic GLM, which was a novel framework introduced by Chowell and Tariq in 2019. One of
the strengths of the model is that it is built on assumptions about exponential growth and can be
applied to different diseases, periods of time, and regions. In addition, the results demonstrated
the ability of the model to identify meaningful information about complex growth dynamics
from simple data, which is notable considering the challenges surrounding collection, use, and
validation of surveillance data. Overall, the model was scalable, easily modified, and provided
results quickly once the programming was set up.
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Another strength of the investigation was that the methodology for measuring uncertainty
was able to identify the two seasons that did not align with underlying virologic transmission
dynamics. Measures of model fit, such as RMSE and MAE, were not by themselves sufficient to
identify this, but the parameter identifiability metrics obtained through bootstrapping provided
another tool for evaluation. Overall, the process developed for fitting and evaluating the model,
including the least squares curve-fitting and bootstrapping, were shown to be comprehensive and
necessary.
In practice, there is a need to obtain results in real time, which means the full shape of the
epidemic curve is not going to be available. It would be beneficial to further investigate the
accuracy of the sub-epidemic model when applied to the early growth period of the influenza
season. Preliminary results were explored during this investigation by applying the methodology
to the early growth period of the 2018–2019 season. The sub-epidemic model fit and
bootstrapping process was repeated on a series of seven time periods with an increasing number
of data points, starting at 6 data points and sequentially increasing until 12 data points. The
preliminary results showed that model fit to the early growth period was also improved by
incoporating sub-epidemics into the GLM. However, more thorough investigation is needed to
understand how the model performs with a number of data points fewer than 30.
One of the limitations of the investigation was the nonspecific definition of epidemic
periods, which added noise into the data. The start and end periods were standardly defined for
consistency and to control factors that might affect model comparison. Further development of
the methodology around how to precisely determine the epidemic threshold is needed to improve
the results. Suggestions in the literature include use of a baseline (Xu et al. 2019; WHO, 2015),
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identification of monotonic increases (Viboud, Simonsen & Chowell, 2016), or use of an
algorithm such as the Nelder-Mead simplex algorithm (Charu et al., 2017).
Finally, more investigation is needed to understand how to translate the information
gained from modeling ILI counts for application to influenza dynamics. Since the influenza
surveillance system into the U.S. monitors several components to understand influenza activity,
it would be valuable to see how other types of influenza surveillance data could contribute to the
model process and whether or not other data sources are more appropriate.
5.3 Conclusion
There is value in the use and validation of phenomenological and parsimonious models
that can quickly generate meaningful results on simple epidemic curve data. The GLM, in all of
its forms, generated meaningful results when applied to a period of epidemic growth for seasonal
influenza. Incorporating sub-epidemics (n=2 or n=3) into the GLM improved model performance
and fit. Most significantly, the sub-epidemic model identified unique characteristics of each
season that were not immediately observable from the aggregate epidemic curve. For two of the
four seasons investigated, model sub-epidemics were aligned with underlying virologic
transmission trends. For the two seasons that were not aligned with virologic results, the
methodology for determining uncertainty around parameter estimates indicated relatively high
uncertainty. These findings support the continued use of this model for academic and other
public health application.
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APPENDIX
Table 4 Parameter estimates and confidence intervals determined from bootstrapping with 200
realizations.
Model Type

Growth Rate (r)

2015–2016 SEASON
GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

2016-2017 SEASON
GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

2017-2018 SEASON
GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

2018-2019 SEASON
GLM 1 Sub-Epidemic
GLM 2 Sub-Epidemics
GLM 3 Sub-Epidemics

Growth Scaling Factor (p)

r: 0.180 (0.178, 0.182)
r1: 6.13 (5.75, 6.47)
r2: 0.0840 (0.0835, 0.0853)
r1: 5.81 (2.74, 9.04)
r2: 0.415 (0.153, 2.93)
r3: 0.0100 (0.0864, 0.131)

p: 0.887 (0.885, 0.889)
p1: 0.477 (0.471, 0.484)
p2: 1.00 (0.996, 1.00)
p1: 0.495 (0.416, 0.601)
p2: 0.871 (0.567, 0.967)
p3: 0.979 (0.934, 1.00)

K: 195,496 (194689, 196369)
K1: 163,841 (159063, 167677)
K2: 98,335 (96856, 100106)
K1: 134,163 (21407, 193744)
K2: 14,541 (3588, 46295)
K3: 116,813 (95696, 165513)

r: 0.329 (0.326, 0.332)
r1: 0.118 (0.114, 0.122)
r2: 1.41 (1.36, 1.47)
r1: 0.673 (0.632, 0.705)
r2: 0.103 (0.102, 0.106)
r3: 0.0822 (0.0765, 0.0889)

p: 0.837 (0.836, 0.838)
p1: 0.966 (0.961, 0.970)
p2: 0.665 (0.661, 0.670)
p1: 0.767 (0.760, 0.776)
p2: 0.999 (0.994, 1.00)
p3: 0.996 (0.977, 1.00)

K: 336,897 (335785, 337988)
K1: 135,211 (131105, 139399)
K2: 230,647 (226243, 234652)
K1: 120,966 (113199, 126581)
K2: 136,165 (131386, 143287)
K3: 85,684 (81967, 96185)

r: 0.347 (0.278, 0.459)
r1: 0.874 (0.860, 0.888)
r2: 0.110 (0.110, 0.112)
r1: 0.114 (0.113, 0.117)
r2: 0.657 (0.641, 0.675)
r3: 0.0780 (0.0692, 0.0788)

p: 0.861 (0.826, 0.883)
p1: 0.756 (0.754, 0.757)
p2: 1.00 (1.00, 1.00)
p1: 1.00 (0.995, 1.00)
p2: 0.791 (0.788, 0.795)
p3: 0.992 (0.980, 1.00)

K: 627,748 (625015, 629841)
K1: 386,670 (383192, 389191)
K2: 275,426 (272855, 279145)
K1: 294,312 (287170, 307218)
K2: 325,660 (310845, 336819)
K3: 39,205 (34288, 44255)

r: 0.362 (0.313, 0.401)
r1: 0.825 (0.179, 1.48)
r2: 0.772 (0.701, 0.951)
r1: 0.202 (0.139, 0.206)
r2: 2.84 (1.67, 3.12)
r3: 0.197 (0.154, 1.13)

p: 0.820 (0.807, 0.839)
p1: 0.773 (0.674, 0.913)
p2: 0.732 (0.685, 0.785)
p1: 0.902 (0.900, 0.944)
p2: 0.638 (0.623, 0.674)
p3: 0.988 (0.781, 1.00)

K: 223,449 (223449, 223450)
K1: 413,798 (339294, 469474)
K2: 140,316 (97702, 192223)
K1: 471,806 (303,216, 480983)
K2: 63,854 (56659, 65356)
K3: 68,265 (61624, 68875)

A) n=1

B) n=2
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Figure 12 Results from the 2015–2016 season. The type and count of viral specimens reported from public
health laboratories are shown along with the GLM sub-epidemic best fit model results obtained from fitting to
the ILI adjusted incidence. A) Results from the GLM with 1 sub-epidemic. B) Results from the GLM with 2
sub-epidemics. 3) Results from the GLM with 3 sub-epidemics.
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Figure 13 Results from the 2016–2017 season. The type and count of viral specimens reported from public
health laboratories are shown along with the GLM sub-epidemic best fit model results obtained from fitting to
the ILI adjusted incidence. A) Results from the GLM with 1 sub-epidemic. B) Results from the GLM with 2
sub-epidemics. 3) Results from the GLM with 3 sub-epidemics.
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Figure 14 Results from the 2017–2018 season. The type and count of viral specimens reported from public
health laboratories are shown along with the GLM sub-epidemic best fit model results obtained from fitting to
the ILI adjusted incidence. A) Results from the GLM with 1 sub-epidemic. B) Results from the GLM with 2
sub-epidemics. 3) Results from the GLM with 3 sub-epidemics.
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Figure 15 Results from the 2018–2019 season. The type and count of viral specimens reported from public
health laboratories are shown along with the GLM sub-epidemic best fit model results obtained from fitting to
the ILI adjusted incidence. A) Results from the GLM with 1 sub-epidemic. B) Results from the GLM with 2
sub-epidemics. 3) Results from the GLM with 3 sub-epidemics.
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